Diagnostic Method for Predicting Increased Risk of Coronary Artery Disease

Case ID:
OSU-19-42
Web Published:
3/5/2020
Description:

Technology Description

Oregon State University is seeking a licensee to develop and commercialize products based on a method for detecting a subject's oxylipin level to predict or determine the subject’s risk for or stage of coronary artery disease (CAD). This method is dependent on the inventors' discovery that the presence and number of obstructed coronary arteries may be linked to certain circulating oxylipin concentrations. Thus, measuring a subject's concentration of particular circulating oxylipins may serve as indicator of the presence or stage of CAD and provide physicians with a fast and economical way to determine a patient's risk for CAD.

Features & Benefits

  • Correlation of the concentration of particular oxylipins in human plasma with the number of obstructed arteries.
  • Provides a possible diagnostic tool to triage patients at risk for CAD.

Applications

  • Diagnostics tests
  • Screening tests
  • Patient triage

Background of Invention

Coronary artery disease usually occurs when cholesterol-containing deposits in an individual’s major blood vessels cause arterial obstruction. It is the most common cause of heart disease in the United States. Patients who may be at risk may be subject to an array of tests, including electrocardiogram, exercise stress tests, chest x-rays, cardiac catheterization, coronary angiogram, and coronary artery scans.

Status

Patent Pending (U.S. provisional patent application)

   

Patent Information:
Category(s):
Diagnostics
For Information, Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Manuel Garcia-Jaramillo
Gerd Bobe
Claudia Maier
Donald Jump
Armando Alcazar Magana
Elizabeth Le
Sanjiv Kaul
Nabil Alkayed
Keywords:
artery
CAD
coronary
Diagnostic
heart disease
© 2020. All Rights Reserved. Powered by Inteum